Clinical trial data on two COVID-19 vaccines are less protective versus the South Africa coronavirus variant. Novavax reported midstage trial results on Thursday that showed its vaccine was 50% effective overall at preventing COVID-19 among people in South Africa. United Kingdom vaccine results were up to 89.3% effective at preventing COVID-19. Pfizer and Moderna vaccines were around 95% in trials conducted before the new variants spread. Pfizer Chief Executive Albert Bourla said there was “a high possibility” that emerging variants may eventually render the company’s vaccine ineffective. Last week,
The post Vaccine Effectiveness Drops from 90% to 50% Versus South Africa Variant first appeared on NextBigFuture.com.
Comments
Post a Comment